Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

PatientPowered.us wins PCORI clinical trial matchmaking app competition

In the years since the Affordable Care Act birthed the Patient-Centered Outcomes Research Institute, the group has committed resources to lowering barriers between those who participate in and run clinical trials. The latest element of this initiative has now come to fruition, with PCORI naming PatientPowered.us as the winner of its Matchmaking App Challenge.

The FDA commits $16M to track prescription drug use

The FDA has set aside $16 million for tracking which drugs are used, in what combinations and for how long, Regulatory Focus reports.

NIH backs database-driven approach to neuromuscular research

The National Institutes of Health (NIH) has awarded a clutch of big-name academic centers funding to create a database for studying motor neuron disorders. By embarking on a large-scale data generation drive and analyzing the resulting information, the collaborators hope to build profiles for Lou Gehrig's disease and other neuromuscular conditions.

Medidata stung by $4.8M wire transfer fraud

Medidata has promised to review its financial controls after fraudsters made away with $4.8 million. Midlevel employees in the eClinical company's finance department reportedly made the transfer to an overseas bank account after receiving a request for $4.8 million.

FDA's Mini-Sentinel set to graduate on October 1

The FDA's Mini-Sentinel has long since outgrown its "mini" moniker and is now ready to graduate from being a pilot project to being an integral part of the agency's drug-safety infrastructure. Many people welcome the program's progress, but doubts and dissenting voices remain.

BIO, PhRMA seek FDA reassurance over scope of Twitter guidance

The window for commenting on the FDA's draft guidance on pharma's use of Twitter and other social media slammed shut last week, leaving the agency with a stack of feedback to consider. Many of the respondents are unhappy with the draft, which was called unconstitutional and overbroad.

BBK bags $3M to expand its eClinical suite

BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.

Merck survey finds patients willing to share NGS data with pharma companies

With pharma companies fretting about the cost of co-developing biomarkers for cancer drugs during early development, Merck staffers have proposed a novel solution: Pay for patients to have their tumors sequenced. Survey data suggest patients are open to the idea.

Stanford and Duke to trial Apple's HealthKit for remote data collection

Apple rolled out the latest iteration of its mobile operating system this week, but users will have to wait until the end of the month to get hold of the much-discussed HealthKit platform.

Vivametrica makes pitch for mHealth data aggregation and analysis market

The market for mHealth data aggregation platforms has become increasingly congested over the past year, with Apple and Google joining the more healthcare industry-focused Validic. Now Vivametrica has joined the space, outlining plans for a platform that fixes the inconsistencies in data from consumer mHealth products and combines them with outputs from medical devices.